Hosted on MSN6h
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorAclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback